09:37 AM EDT, 06/16/2025 (MT Newswires) -- AbbVie ( ABBV ) said Monday that a global phase 3 trial assessing venetoclax plus azacitidine in treating newly diagnosed higher-risk myelodysplastic syndrome did not meet the primary endpoint for overall survival.

The company said there were no observed new safety signals.

The company also said that any current approved indications for venetoclax are not impacted by the data.

Price: 190.05, Change: -1.00, Percent Change: -0.52